2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 2938

U4ATAC Mutation Is Associated with an Immune Dysregulation Syndrome Characterized By Primary Immunodeficiency, Short Stature and Polyglandular Endocrinopathy
Abstract Number: 1265

Ultra-High Field MRI and Biomechanical Investigation of Vertebral Bone Microarchitecture
Abstract Number: 147

Ultrasonographic Evaluation of Subclinical Enthesitis in Patients with Psoriasis
Abstract Number: 960

Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study
Abstract Number: 150

Ultrasonography and Magnetic Resonance Imaging Changes in Polymyalgia Rheumatica Patients Treated By Tocilizumab
Abstract Number: 1003

Ultrasonography Changes during the Course of Septic Arthritis ARE Associated with Functional Outcome
Abstract Number: 1401

Ultrasonography of Major Salivary Glands in Juvenile SjöGren’s Syndrome − Preliminary Findings in a Multi-Center Study
Abstract Number: 3029

Ultrasonography of Major Salivary Glands in Patients Suspected with Primary Sjögren’s Syndrome: Comparison with Salivary Gland Biopsy and Classification Criteria
Abstract Number: 2604

Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Abstract Number: 169

Ultrasound and Magnetic Resonance Imaging Fusion of Images and B-Flow Evaluation of Tenosynovitis – a Pilot Study on New Imaging Techniques in Rheumatoid Arthritis Patients
Abstract Number: 160

Ultrasound Assessment of Rheumatoid Arthritis Patients. External Validation and Inter-Rater Reliability of a 4-Joint Ultrasonographic Scoring System
Abstract Number: 857

Ultrasound Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis
Abstract Number: 3197

Ultrasound Definitions for Cranial and Large Vessel Giant Cell Arteritis: Results of a Reliability Exercise on Images and Videos of the Omeract Ultrasound Large Vessel Vasculitis Task Force
Abstract Number: 3127

Ultrasound Evaluation of the Achilles Tendon in Tophaceous Gout: A Case-Control Study
Abstract Number: 3055

Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricaemia: Comparison with Normouricaemic Individuals
Abstract Number: 146

Ultrasound Features of the Posterior Tibialis Tendon and Peroneus Brevis Tendon Entheses: A Comparison Study Between Healthy Adults and Inflammatory Arthritis
Abstract Number: 2330

Ultrasound Imaging in Inclusion Body Myositis
Abstract Number: 221

Ultrasound in Gout: The Clinical Application
Abstract Number: 1976

Ultrasound Inflammation in Patients Presenting with Arthralgia Is Associated with Developing Arthritis
Abstract Number: 129

Ultrasound Is More Reliable Than Inflammatory Parameters (ESR and CRP) to Evaluate Disease Activity in Rheumatoid Arthritis Patients on Tocilizumab Therapy
Abstract Number: 2685

Ultrasound of the Major Salivary Glands Is a Reliable Imaging Technique for Diagnosing Patients Clinically Suspected with SjöGren’s Syndrome
Abstract Number: 132

Ultrasound Performed Among RA Patients in Real Life Setting Can Predict Loss of Remission, Especially When Done Early after Reaching Remission
Abstract Number: 1354

Ultrasound Verified Inflammation and Structural Abnormalities in Patients with Hemochromatosis with and without Associated Arthropathy
Abstract Number: 2334

Ultrasound-Guided Facet Joint Injections through a Longitudinal Approach
Abstract Number: 1187

Ultraviolet Radiation Exposures Are Associated with Dermatomyositis in a National Myositis Registry
Abstract Number: 2871

Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Abstract Number: 567

Understanding Contextual Factors That Influence Decisions Related to Health and Work Among People with Recently Diagnosed Rheumatoid Arthritis
Abstract Number: 1241

Understanding Lupus Patients’ Ability to Work with Numbers
Abstract Number: 2342

Understanding Patient Barriers and Facilitators to Healthy Eating and Physical Activity before and after Knee Replacement
Abstract Number: 81

Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Abstract Number: 1345

Undifferentiated Connective Tissue Disease: A 121 Patients Audit Focusing on Initial Diagnosis and Changes over Time
Abstract Number: 2764

Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample
Abstract Number: 2130

Unloading Results in Rapid Loss of TGFβ Signaling in Cartilage: Role of Loading-Induced TGF-Β Signaling in Maintenance of Articular Chondrocyte Phenotype?
Abstract Number: 258

Unmet Psychosocial Needs in Patients with CAPS
Abstract Number: 788

Unresolving C4 Hypocomplementemia Associates with a Different Spectrum of Disease in SLE and Is More Important Than Transiently Low Levels
Abstract Number: 2576

uPAR Promotes Tumor-like Biologic Role of Fibroblast-like Synoviocytes through PI3K/Akt Signaling Pathway in Patients with Rheumatoid Arthritis
Abstract Number: 2391

Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 80 Patients at First Assessment
Abstract Number: 1685

Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Abstract Number: 1684

Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Abstract Number: 184

Upregulation and Activation of the IFI16-Sting-IRF3-IFN Pathway in Sjogren’s Salivary Glands
Abstract Number: 3199

Urate Crystal Deposition and Bone Erosion in Gout: Inside-out or Outside-in? a Dual Energy Computed Tomography Study
Abstract Number: 912

Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease
Abstract Number: 220

Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout
Abstract Number: 2294

Uric Acid Production and Blood Pressure: The Role of Uric Acid Concentration As Well As Uric Acid Production
Abstract Number: 2823

Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
Abstract Number: 2825

Urinary BAFF and APRIL Levels: Potential Biomarkers of Active Lupus Nephritis
Abstract Number: 1865

Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis
Abstract Number: 2858

Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Abstract Number: 968

Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
Abstract Number: 996

Use of a Shared Medical Appointment for Patients with Fibromyalgia in a Rural, Academic Medical Center: A Process Improvement Initiative for the Development of a New Care Model
Abstract Number: 1322

Use of Biologics in Arthritis Patients with Hepatitis B and C ‏: A Multicentral Retrospective Case Series
Abstract Number: 634

Use of Biosimilars in Clinical Practice: A Swedish National Register-Based Assessment
Abstract Number: 429

Use of Electronic Medical Record to Identify Immunocompromised Patients in a Pediatric Rheumatology Clinic
Abstract Number: 1342

Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports
Abstract Number: 14L

Use of Intravenous Epoprostenol As a Treatment for the Digital Vasculopathy Associated with the Scleroderma Spectrum of Diseases
Abstract Number: 2944

Use of Muscle Biopsies for the Diagnosis of Systemic Vasculitis in a Rheumatology Service
Abstract Number: 789

Use of Nominal Group Technique to Determine Candidate Items for SLE Classification Criteria Development
Abstract Number: 2442

Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis
Abstract Number: 995

Use of Opiate Diminished the Treatment Benefits of Motivational Interviewing for Fibromyalgia
Abstract Number: 501

Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis
Abstract Number: 1159

Use of Rheumatology-Specific Patient Navigators for DMARD Adherence: Results from a Pilot Intervention
Abstract Number: 3062

Use of Script Concordance Testing to Evaluate the Efficacy of a Web-Based Module on Gout: Three Years of Experience
Abstract Number: 1338

Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease
Abstract Number: 3254

Use of the Short Valued Life Activities Scale in People with Systemic Sclerosis
Abstract Number: 417

Use of Tumor Necrosis Factor-α Inhibitors in Pediatric HLA-B27-Associated Uveitis
Abstract Number: 390

Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India
Abstract Number: 502

Use, Usability and Feasibility of a Mapp for Patients with Rheumatoid Arthritis – First Results
Abstract Number: 2888

Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis
Abstract Number: 2893

Usefulness of the Eustar Preliminary Criteria for Vey Early Systemic Sclerosis and Le Roy Criteria for Early-Systemic Sclerosis in Identifying Patients at Risk of Development of Systemic Sclerosis
Abstract Number: 967

Using a Hazard Index Tool Based on Short Term Renal Parameters to Predict Long Term Outcomes in Lupus Nephritis: A Novel Way to Assess New Therapies
Abstract Number: 305

Using a Large Prospective Cohort of Patients to Examine Differences in Performance and Self-Reported Outcomes Following Total Knee Replacement
Abstract Number: 1157

Using Goutpro to Make Medical Trainees Gout Pros
Abstract Number: 2635

Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA
Abstract Number: 1423

Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Abstract Number: 1426

Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis
Abstract Number: 787

Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
Abstract Number: 1707

Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 1718

Ustekinumab, Apremilast, TNFi and the Risk for Hospitalized Infection in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 862

Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis
Abstract Number: 1293

Utility of Extremity Magnetic Resonance Imaging (eMRI) without Contrast Enhancement in Detecting Preclinical Psoriatic Arthritis
Abstract Number: 1283

Utility of FDG-PET Imaging and Serological Biomarkers for Diagnosing Lymphadenopathy of IgG4-Related Diseas
Abstract Number: 3180

Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Abstract Number: 999

Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis
Abstract Number: 3083

Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures
Abstract Number: 545

Utility of Power Doppler Ultrasound-Detected Synovitis for the Prediction of Short Term Flare in Rheumatoid Arthritis Patients in Clinical Remission
Abstract Number: 1464

Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age
Abstract Number: 1465

Utility of Relative Cardiovascular Risk Score Scales in Patients UNDER the Age of 50 and Its Association with the Presence of Carotid Atherosclerosis in the Ultrasound
Abstract Number: 2834

Utility of the Brain Perfusion Single Photon Emission Computed Tomography in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Abstract Number: 2012

Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus
Abstract Number: 1287

Utility of Vascular Findings By PET/CT Scan in the Diagnosis and Activity Assesment of Takayasu Arteritis
Abstract Number: 2235

Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By RA Patients: A 13 Year Population Health Study
Abstract Number: 2546

Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer
Abstract Number: 908

Utilization of Multiple Acute Phase Proteins and Biomarkers for Giant Cell Arteritis – Insight into Diagnosis and Clinical Complications
Abstract Number: 2744

Utilization of the Psoriasis Epidemiology Screening Tool (PEST) Questionnaire to Detect Psoriatic Arthritis in Clinical Practice: Data from the Validation of Psoriatic Arthritis Screening Tool for Korean Psoriasis Patients (VALOR) Study
Abstract Number: 2244

Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients
Abstract Number: 416

Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].